FTC Sues OptumRx and Competitors Over Insulin Pricing

On Friday, Express Scripts issued a statement saying the commission was “choosing to ignore the facts and score political points, rather than focusing on its duty to protect consumers.”

Caremark Rx, a division of Rhode Island-based CVS Health, said in a statement: “Three brand-name drugmakers control nearly the entire insulin market and, without competing lower-cost generic alternatives, they raised their list prices by as much as 500 percent at the same time prior to 2012. It was at this time that CVS Caremark fueled increased competition by creating new formulary options to combat these manufacturer price increases.”